Treatment
Cisplatin or Carboplatin clinical trials
We’re tracking 805 recruiting studies that include Cisplatin or Carboplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT05978648RecruitingPhase 2
Trilaciclib for early-stage HR-negative breast cancer after surgery
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
Guangzhou, GangdongAges 18 years+ - NCT05981001RecruitingPhase 1/Phase 2
Experimental cell therapy for advanced HER2-negative breast cancer
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
Guangzhou, GuangdongAges 18–70 - NCT05983276RecruitingPhase 2
Combination therapy for drug-resistant ovarian cancer
This trial tests a new two-drug combination (decitabine and selinexor) given with standard chemotherapy to see if it can reverse drug resistance in ovarian cancer that has come back or worsened after treatment.
Maywood, IllinoisAges 18 years+ - NCT05991388RecruitingPhase 2/Phase 3
New treatments for children with relapsed B-NHL
This trial tests two new treatment combinations for children and young adults with B-cell non-Hodgkin lymphoma that has come back or not responded to previous therapy. The goal is to find better options for treating this cancer.
Sydney, New South WalesAges Up to 25 years - NCT06001151RecruitingPhase 2
Cadonilimab plus chemo for PD-L1 negative lung cancer
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy as a first treatment for people with advanced non-squamous non-small cell lung cancer that does not have the PD-L1 protein. The goal is to see if this combination works better than standard treatments.
Wuhan, HubeiAges 18–75 - NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06019130RecruitingPhase 2
Nivolumab for newly diagnosed nasopharyngeal cancer
This trial tests whether the immunotherapy drug nivolumab (Opdivo) can help treat nasopharyngeal cancer in both children and adults. It is for people who have just been diagnosed and have not yet received any cancer treatment.
AachenAges 3 years+ - NCT06022861RecruitingPhase 3
Study of LY01015 vs Opdivo with chemo for advanced esophageal cancer
This trial tests a new drug, LY01015, against Opdivo when both are given with chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. It aims to see if LY01015 works as well as Opdivo and has similar safety.
GuangzhouAges 18–75 - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06081673RecruitingPhase 2
Penpulimab plus chemo before and after surgery for head and neck cancer
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06087614RecruitingPhase 2
Higher-dose radiation for head and neck cancer
This trial tests a higher dose of radiation therapy that is adjusted based on oxygen levels in the tumor. It may help people with certain head and neck cancers that have not been treated before.
DelhiAges 18–70 - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06100497RecruitingPhase 2
PD-1 plus chemo for advanced head and neck cancer
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06110572RecruitingPhase 1/Phase 2
Total body irradiation with immunotherapy for extensive SCLC
This trial adds total body irradiation (a low dose of radiation to the whole body) to standard atezolizumab (immunotherapy) plus chemotherapy for people with extensive-stage small cell lung cancer. The goal is to see if the radiation helps the immunotherapy work better.
Nashville, TennesseeAges 18 years+ - NCT06122493RecruitingPhase 2
Better treatment for advanced esophageal cancer
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06138561Recruiting
Bladder cancer treatment study for older adults
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
Boston, MassachusettsAges 65 years+ - NCT06140966RecruitingPhase 2
Daratumumab and Carfilzomib combo for high-risk multiple myeloma
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
Wuhan, HubeiAges 18–70 - NCT06145308RecruitingPhase 2
Precision treatment for salivary gland cancer
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Beijing, Beijing MunicipalityAges 18–100 - NCT06144736RecruitingPhase 2
Surgery for stage 2 seminoma testicular cancer trial
This trial is testing whether removing affected lymph nodes with surgery (RPLND) works well alone for seminoma testicular cancer that has spread to nearby nodes but is still relatively small. It is for patients who have not had extensive chemo or radiation.
DüsseldorfAges 18–99 - NCT06173986RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for advanced esophageal cancer
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
ShanghaiAges 18–75 - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06208826RecruitingPhase 2
Immunotherapy maintenance after surgery for head and neck cancer
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT06209294RecruitingPhase 2
New drug combo before fertility-sparing surgery for cervical cancer
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT06215976RecruitingPhase 4
Metformin with cisplatin for bladder cancer: protecting kidneys
This trial tests if adding metformin to cisplatin chemotherapy can protect the kidneys of people with bladder cancer. It may help reduce kidney damage from cisplatin treatment.
CairoAges 18–65
Common questions
- Are there clinical trials studying Cisplatin or Carboplatin?
- Yes. Clin2 currently lists 805 recruiting studies that include Cisplatin or Carboplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cisplatin or Carboplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cisplatin or Carboplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cisplatin or Carboplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.